Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Gionata Fiorino, Carmen Correale, Walter Fries, Alessandro Repici, Alberto Malesci & Silvio Danese. (2010) Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Review of Clinical Immunology 6:4, pages 567-572.
Read now
Read now
Articles from other publishers (15)
Esther S. FrischDarius HäuslerMartin S. Weber. (2023) Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 10:4.
Crossref
Crossref
Ahamd Elssayed, Rana Ibrahim AlRgaiba, Mohammed Khalid AlZalbani, Mohammed Rajab Jumah Hassan, Khalid Humaid AlMalki, Abdulaziz Ali AlGhannam, Ziyad Fahad AlMudayfir, Hind Ali Abdourab Mohamed, Malak Motia Sheikh, Abdulmalek Ali AlGhamdi & Sarah Ibrahem AlMarwani. (2023) Review on Diagnosis and Management Approach of Multiple Sclerosis. International Journal of Pharmaceutical Research And Allied Sciences 12:1, pages 100-105.
Crossref
Crossref
Jean-Marc Schwob, Caroline F Samer, Patrice H Lalive & Gilles A Eperon. (2021) Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit–risk assessment for natalizumab. Journal of Travel Medicine 28:3.
Crossref
Crossref
Jessica R. Lakritz, Derek M. Thibault, Jake A. Robinson, Jennifer H. Campbell, Andrew D. Miller, Kenneth C. Williams & Tricia H. Burdo. (2016) α4-Integrin Antibody Treatment Blocks Monocyte/Macrophage Traffic to, Vascular Cell Adhesion Molecule-1 Expression in, and Pathology of the Dorsal Root Ganglia in an SIV Macaque Model of HIV-Peripheral Neuropathy. The American Journal of Pathology 186:7, pages 1754-1761.
Crossref
Crossref
Neda Ebrahimi, Sandra Herbstritt, Ralph Gold, Lilyana Amezcua, Gideon Koren & Kerstin Hellwig. (2014) Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Multiple Sclerosis Journal 21:2, pages 198-205.
Crossref
Crossref
Jennifer H. Campbell, Eva-Maria Ratai, Patrick Autissier, David J. Nolan, Samantha Tse, Andrew D. Miller, R. Gilberto González, Marco Salemi, Tricia H. Burdo & Kenneth C. Williams. (2014) Anti-α4 Antibody Treatment Blocks Virus Traffic to the Brain and Gut Early, and Stabilizes CNS Injury Late in Infection. PLoS Pathogens 10:12, pages e1004533.
Crossref
Crossref
Michael Kaufman, Gabriel Pardo, Howard Rossman, Marianne T. Sweetser, Fiona Forrestal & Petra Duda. (2014) Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences 341:1-2, pages 22-27.
Crossref
Crossref
Krista G. Haanstra, Sam O. Hofman, Dave M. Lopes Estêvão, Erwin L. A. Blezer, Jan Bauer, Li-Li Yang, Tim Wyant, Vilmos Csizmadia, Bert A. ‘t Hart & Eric R. Fedyk. (2013) Antagonizing the α4β1 Integrin, but Not α4β7, Inhibits Leukocytic Infiltration of the Central Nervous System in Rhesus Monkey Experimental Autoimmune Encephalomyelitis. The Journal of Immunology 190:5, pages 1961-1973.
Crossref
Crossref
C. Frieke Kuper, Christine Ruehl-Fehlert, Susan A. Elmore & George A. Parker. 2013. Haschek and Rousseaux's Handbook of Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology
1795
1862
.
Eric R. Fedyk, Tim Wyant, Li-Li Yang, Vilmos Csizmadia, Kristine Burke, Hua Yang & Vivek J. Kadambi. (2012) Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflammatory Bowel Diseases 18:11, pages 2107-2119.
Crossref
Crossref
Asit Parikh, Timothy Leach, Tim Wyant, Catherine Scholz, Serap Sankoh, Diane R. Mould, Terry Ponich, Irving Fox & Brian G. Feagan. (2012) Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study. Inflammatory Bowel Diseases 18:8, pages 1470-1479.
Crossref
Crossref
Peter J Bugelski & Pauline L Martin. (2012) Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. British Journal of Pharmacology 166:3, pages 823-846.
Crossref
Crossref
LaRonda L. Morford, Christopher J. Bowman, Diann L. Blanset, Ingrid B. Bøgh, Gary J. Chellman, Wendy G. Halpern, Gerhard F. Weinbauer & Timothy P. Coogan. (2011) Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices. Birth Defects Research Part B: Developmental and Reproductive Toxicology, pages n/a-n/a.
Crossref
Crossref
Patcharica Meteesatien, Scott E Plevy, Justin D. Fender & Yuri Fedoriw. (2010) Circulating Blasts in a Crohn’s Patient Treated With Natalizumab. Laboratory Medicine 41:8, pages 453-456.
Crossref
Crossref
Nancy G. Wehner, George Shopp, Ingrid Osterburg, Antje Fuchs, Eberhard Buse & Janet Clarke. (2009) Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor. Birth Defects Research Part B: Developmental and Reproductive Toxicology 86:2, pages 144-156.
Crossref
Crossref